Previsão de demanda de potência em sistema híbrido de armazenamento de energia em veículos elétricos utilizando redes Narx/ Power demand forecasting on hybrid energy storage system in electric vehicles using Narx networks

O uso de múltiplas fontes de energia na alimentação de veículos puramente elétricos possibilita melhorar seu desempenho, aumentando sua autonomia e prolongando a vida útil do banco de baterias embarcado, que é o elemento de maior custo deste tipo de automóvel. Neste trabalho, é proposto o uso de técnicas de inteligência computacional na gestão de um sistema híbrido de armazenamento de energia baseado em bateria e supercapacitor, ambos embarcados em um veículo elétrico. Para isso, é apresentada uma metodologia de previsão e separação da demanda das frações de potência utilizando uma rede neural baseada no Modelo Autorregressivo Não Linear com Entradas Exógenas (NARX). A partir das simulações realizadas e dos ajustes dos parâmetros da rede, encontrou-se um erro muito pequeno em relação aos sinais previstos. Com base nos resultados obtidos é possível concluir que o método proposto se mostrou bastante eficiente e promissor para a aplicação em cálculo de demanda de energia em veículos elétricos

Desafios e avanços na antibioticoterapia para exacerbações pulmonares na fibrose cística

A fibrose cística é uma doença genética complexa que afeta a produção de muco e a função pulmonar. Exacerbações pulmonares, muitas vezes provocadas por Pseudomonas aeruginosa, são comuns. O diagnóstico requer testes de suor e genéticos para guiar a terapia antibiótica. Avanços com moduladores CFTR melhoram a função pulmonar, mas desafios como resistência bacteriana persistem. Este estudo busca analisar a antibioticoterapia para exacerbações pulmonares na fibrose cística, com foco em abordagens inovadoras e personalizadas. O estudo, baseado em uma revisão sistemática da literatura científica, abrange o período de 2016 a 2024, utilizando as bases de dados PubMed (Medline), Cochrane Library e Scientific Electronic Library Online (SciELO). No primeiro estudo, sobre adjuvantes antibióticos no tratamento de infecções pulmonares em pacientes com fibrose cística, não houve impacto significativo nas exacerbações pulmonares ou na função respiratória. O KB001-A não alterou o tempo para a próxima administração de antibióticos em comparação ao placebo. Evidências apontam uma possível redução na densidade de Pseudomonas aeruginosa com o KB001-A e reduções em Staphylococcus aureus e quase-Pseudomonas aeruginosa com o óxido nítrico, sem diferenças na qualidade de vida. O segundo estudo, em um modelo suíno de pneumonia por Pseudomonas aeruginosa multirresistente, a terapia inalatória de amicacina combinada com meropenem mostrou maior eficácia bactericida nas secreções traqueais em comparação à monoterapia intravenosa. A administração inalatória não preveniu a disseminação da infecção, mas a amicacina evitou o aumento da concentração inibitória mínima de meropenem, com alta concentração nas amostras sem diferenças entre pulmões infectados e não infectados. No terceiro estudo, O estudo das nanopartículas poliméricas na eliminação de biofilmes bacterianos em cepas resistentes e suscetíveis associadas à fibrose cística mostrou potencial promissor contra bactérias multirresistentes. Os nanoportadores de lipídios demonstraram eficácia terapêutica significativa, ressaltando a necessidade de mais pesquisas para confirmar seu benefício clínico. Em resumo, os adjuvantes antibióticos não impactaram significantemente o tratamento de infecções pulmonares na fibrose cística. A combinação de amicacina e meropenem foi eficaz contra pneumonia por Pseudomonas aeruginosa multirresistente. As nanopartículas poliméricas e nanoportadores de lipídios mostraram potenciais terapêuticos promissores, demandando mais pesquisas para validar seus benefícios clínicos

Nurses' perceptions of aids and obstacles to the provision of optimal end of life care in ICU

Contains fulltext : 172380.pdf (publisher's version ) (Open Access

Doença pulmonar obstrutiva crônica no cenário da pandemia da COVID-19: guia de orientações e exercícios

This e-book was prepared by the group of researchers, professors and students from the Research Laboratory in Pulmonary Evaluation and Rehabilitation at UFRJ (LiRP / UFRJ) and had the collaboration of a multiprofessional team with extensive experience in Pulmonary Rehabilitation. The e-book originated from a demand from patients with chronic obstructive pulmonary disease (COPD), their caregivers, family and friends in relation to the better management of this disease during the COVID-19 pandemic.Esse e-book foi elaborado pelo grupo de pesquisadores, professores e alunos do Laboratório de Investigação em Avaliação e Reabilitação Pulmonar da UFRJ (LiRP/UFRJ) e contou com a colaboração de uma equipe multiprofissional com vasta experiência em Reabilitação Pulmonar. O e-book foi originado de uma demanda dos pacientes com doença pulmonar obstrutiva crônica (DPOC), seus cuidadores, familiares e amigos em relação ao melhor manejo dessa doença durante a pandemia da COVID-19

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

BACKGROUND: Ischemic stroke is the leading cause of mortality worldwide and a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke. This article describes the rationale and design of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic Attack (PERFORM) Study, which aims to demonstrate the superiority of the efficacy of terutroban versus aspirin in secondary prevention of cerebrovascular and cardiovascular events. METHODS AND RESULTS: The PERFORM Study is a multicenter, randomized, double-blind, parallel-group study being carried out in 802 centers in 46 countries. The study population includes patients aged > or =55 years, having suffered an ischemic stroke (< or =3 months) or a transient ischemic attack (< or =8 days). Participants are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). The primary efficacy endpoint is a composite of ischemic stroke (fatal or nonfatal), myocardial infarction (fatal or nonfatal), or other vascular death (excluding hemorrhagic death of any origin). Safety is being evaluated by assessing hemorrhagic events. Follow-up is expected to last for 2-4 years. Assuming a relative risk reduction of 13%, the expected number of primary events is 2,340. To obtain statistical power of 90%, this requires inclusion of at least 18,000 patients in this event-driven trial. The first patient was randomized in February 2006. CONCLUSIONS: The PERFORM Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic event.Journal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial

Background: Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent stroke or other cardiovascular events. We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaemic events in patients with a recent non-cardioembolic cerebral ischaemic event. &lt;p/&gt;Methods: This randomised, double-blind, parallel-group trial was undertaken in 802 centres in 46 countries. Patients who had an ischaemic stroke in the previous 3 months or a TIA in the previous 8 days were randomly allocated with a central interactive response system to 30 mg per day terutroban or 100 mg per day aspirin. Patients and investigators were masked to treatment allocation. The primary efficacy endpoint was a composite of fatal or non-fatal ischaemic stroke, fatal or non-fatal myocardial infarction, or other vascular death (excluding haemorrhagic death). We planned a sequential statistical analysis of non-inferiority (margin 1·05) followed by analysis of superiority. Analysis was by intention to treat. The study was stopped prematurely for futility on the basis of the recommendation of the Data Monitoring Committee. This study is registered, number ISRCTN66157730. &lt;p/&gt;Findings: 9562 patients were assigned to terutroban (9556 analysed) and 9558 to aspirin (9544 analysed); mean follow-up was 28·3 months (SD 7·7). The primary endpoint occurred in 1091 (11%) patients receiving terutroban and 1062 (11%) receiving aspirin (hazard ratio [HR] 1·02, 95% CI 0·94–1·12). There was no evidence of a difference between terutroban and aspirin for the secondary or tertiary endpoints. We recorded some increase in minor bleedings with terutroban compared with aspirin (1147 [12%] vs 1045 [11%]; HR 1·11, 95% CI 1·02–1·21), but no significant differences in other safety endpoints. &lt;p/&gt;Interpretation: The trial did not meet the predefined criteria for non-inferiority, but showed similar rates of the primary endpoint with terutroban and aspirin, without safety advantages for terutroban. In a worldwide perspective, aspirin remains the gold standard antiplatelet drug for secondary stroke prevention in view of its efficacy, tolerance, and cost

ESICM LIVES 2016: part two : Milan, Italy. 1-5 October 2016.

Meeting abstrac

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

BACKGROUND: Ischemic stroke is the leading cause of mortality worldwide and a major contributor to neurological disability and dementia. Terutroban is a specific TP receptor antagonist with antithrombotic, antivasoconstrictive, and antiatherosclerotic properties, which may be of interest for the secondary prevention of ischemic stroke. This article describes the rationale and design of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic Attack (PERFORM) Study, which aims to demonstrate the superiority of the efficacy of terutroban versus aspirin in secondary prevention of cerebrovascular and cardiovascular events. METHODS AND RESULTS: The PERFORM Study is a multicenter, randomized, double-blind, parallel-group study being carried out in 802 centers in 46 countries. The study population includes patients aged > or =55 years, having suffered an ischemic stroke (< or =3 months) or a transient ischemic attack (< or =8 days). Participants are randomly allocated to terutroban (30 mg/day) or aspirin (100 mg/day). The primary efficacy endpoint is a composite of ischemic stroke (fatal or nonfatal), myocardial infarction (fatal or nonfatal), or other vascular death (excluding hemorrhagic death of any origin). Safety is being evaluated by assessing hemorrhagic events. Follow-up is expected to last for 2-4 years. Assuming a relative risk reduction of 13%, the expected number of primary events is 2,340. To obtain statistical power of 90%, this requires inclusion of at least 18,000 patients in this event-driven trial. The first patient was randomized in February 2006. CONCLUSIONS: The PERFORM Study will explore the benefits and safety of terutroban in secondary cardiovascular prevention after a cerebral ischemic event